immunotherapy
The latest news about immunotherapy: headlines, AI summaries and the full story from every source.
- ImmunityBio Shares Fall 15% Following Third Quarter Earnings Miss
- Johnson & Johnson Experimental Immunotherapy Combination Reduces Prostate Cancer PSA Levels in Early Trial
- Immorta Bio Announces First Human Administration of SenoMune™-0257 Immunotherapy
- Amgen's Imdelltra Combination Therapy Reduces Death Risk by 58% in Extensive-Stage Small Cell Lung Cancer
- Kansai Medical University Hospital Administers First Dose of DS1025 in Global Phase 1 Trial Sponsored by Daiichi Sankyo
- Genmab and AbbVie Report Positive Phase 3 Trial Results for Epkinly in B-cell Lymphoma
- ImmunityBio Shares Rise After Meeting With Turkish President
- Summit Therapeutics' ivonescimab shows 27% lower mortality than Merck's Keytruda in lung cancer trial
- OncoHost to Present New Data on PROphetNSCLC at WCLC 2026
- Summit Therapeutics Shares Rise 28% Following Positive Clinical Trial Results for Ivonescimab
- Summit Therapeutics' Lung Cancer Drug Shows Survival Benefit
- Merck Reports Positive Late-Stage Trial Results for Keytruda
- GSK's Jemperli Shows Sustained Complete Clinical Response in Phase 2 Trial for Rectal Cancer
- Scancell Confirms Advanced Talks for Reverse Merger With Neuphoria Therapeutics
- Moderna and Merck Report Positive Results from mRNA Cancer Vaccine Trial
- Akeso's Lung Cancer Drug Shows Improved Survival in Phase 3 Trial
- Incyte's Monjuvi Shows Improved Cancer-Free Survival in Lymphoma Trial
- ImmunityBio Near Regulatory Approval for Bladder Cancer Immunotherapy
- ImmunityBio Stock Rises on FDA Acceptance for Anktiva Label Expansion
- ImmunityBio Receives FDA Review for Anktiva Label Expansion
- Regeneron Pharmaceuticals Announces Failed Phase 3 Melanoma Trial for Fianlimab Combination Therapy
- Regeneron Announces Failure in Late-Stage Trial of Libtayo Combination Therapy
- Evaxion Q1 2026 Earnings Call Summary and Key Clinical Data
- Immix Biopharma Completes Enrollment for Key Phase 2 Trial
- ImmunityBio Expands ANKTIVA Access to Saudi Arabia